Market Overview

Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod

Share:
Merck's Novel Antibiotic For Abdominal, Urinary Tract Infections Receives FDA Nod

Merck & Co., Inc. (NYSE: MRK) continues to find success with its product pipeline, with another of its treatment options receiving FDA approval. 

Merck announced Wednesday that the FDA OK'd RECARBIO, a combination of imipenem, cilastatin and relebactam in a 1.25g injection formulation.

The drug is intended to treat patients 18 and older for complicated urinary tract infection, or cUTI — including pyelonephritis — caused by some susceptible gram-negative microorganisms and for which there is limited or no alternative treatment options.

The antibacterial medication is also indicated to treat complicated intra-abdominal infections.

"RECARBRIO offers an additional treatment option for patients with cIAI and cUTI who have limited and, in some cases, no alternative therapeutic options," Keith Kaye, a principal investigator of the clinical program that evaluated the antibiotic combo, said in a statement. 

Merck shares were trading higher by 0.42% at $81.93 at the time of publication Wednesday. 

Related Links:

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Washington Worries Trigger Bearish Merck Options Trades

Posted-In: Biotech News FDA Trading Ideas General Best of Benzinga

 

Related Articles (MRK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

In The Thick Of It: Bank Results Highlight Morning, With NFLX At Center Screen Late

What Caused The Opening Gap In Francesca's?